Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sulfur hexafluoride - Bracco

Next Previous
Drug Profile

Sulfur hexafluoride - Bracco

Alternative Names: BRI; E-7210; LUMASON; Lumason; LUMASON UEA; SonoVue; sulfur hexafluoride lipid-type A microspheres; Sulphur hexafluoride

Latest Information Update: 20 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bracco
  • Developer Bracco; Eisai Co Ltd
  • Class Contrast media; Fluorides; Inorganic sulfur compounds; Small molecules
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cerebrovascular disorders
  • Registered Breast disorders; Cardiovascular disorders; Liver disorders; Vesicoureteral reflux
  • Phase III Congenital heart defects

Most Recent Events

  • 10 Jul 2024 Phase-III clinical trials in Cardiovascular disorders (Diagnosis) in USA (IV) (NCT06400004)
  • 10 Jul 2024 Phase-III clinical trials in Cardiovascular disorders (Diagnosis) in USA (Parenteral) (NCT06400004)
  • 30 Apr 2024 Bracco plans a phase III trial for Heart disorders (Diagnosis) in USA (IV, Injection) (NCT06400004)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top